<DOC>
	<DOCNO>NCT02687672</DOCNO>
	<brief_summary>This double-armed , Phase I/II trial aim compare bone marrow leukapheresis source purify , autologous CD34+ CD133+ stem cell ( SCs ) , utilized treatment patient chronic complete spinal cord injury ( SCI ) . The study focus safety efficacy transplant un-manipulated , autologous , purified stem cell injured spinal cord patient .</brief_summary>
	<brief_title>Transplantation Autologous Bone Marrow Leukapheresis-Derived Stem Cells Treatment Spinal Cord Injury</brief_title>
	<detailed_description>Spinal cord injury ( SCI ) lead apoptosis oligodendrocyte injury site result demyelination neuronal degeneration . This degeneration cause severe functional sensory motor mutilation remain immense challenge physician stem cell ( SC ) transplantation represent viable alternative . This study phase I/II trial aim describe method treat patient chronic complete spinal cord injury ( SCI ) utilize autologous , purified CD34+ CD133+ stem cell ( SCs ) . The study focus safety efficacy transplant un-manipulated , autologous , purified stem cell treat patient 5-year follow-up period .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<criteria>Patients suffer chronic spinal cord injury Age injury range 660 month prior enrollment study . Ability willingness regularly visit Jordan Orthopedic Spinal Center post operation follow . Traumatic Injury spinal cord complete partial damage confirm MRI . Injuries le 6 month old 60 month old Nontraumatic injury ( SCI due inflammation , autoimmune disease ) Patients less 5 old 50 year Patients suffer condition , include chronic neurological disease , diabetes mellitus , cardiac/kidney/liver disorder , previous stroke , previous surgery unrelated spinal cord injury .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>